Table 3.

Comparisons of the visual function of the EECP and control groups by systemic health condition

	Hypertension		Diabetes mellitus		Hypercholesterolemia		Ischemic stroke
	Yes	No	Yes	No	Yes	No	Yes	No
No. of eyes	32	44	31	45	26	50	17	59
EECP/Control (n)	17/15	20/24	12/19	25/20	13/13	24/26	7/10	30/29
BCVA
Baseline	0.019a	0.921	0.065	0.625	0.626	0.086	0.059	0.102
	0.99 ± 0.70 vs 1.17 ± 1.07
Month 2	0.885	0.650	0.917	0.826	0.178	0.661	0.035a	0.777
							0.62 ± 0.26 vs 0.95 ± 0.46
Change (2–0)	0.122	0.800	0.087	0.511	0.759	0.308	0.204	0.265
Month 6	0.651	0.091	0.069	0.911	0.063	0.195	0.096	0.051
Change (6–0)	0.250	0.274	0.065	0.847	0.778	0.244	0.163	0.089
MD
Baseline	0.063	0.901	0.153	0.797	0.394	0.453	0.849	0.134
Month 2	0.038a	0.422	0.106	0.662	0.814	0.474	0.650	0.425
	−21.88 ± 7.02 vs −19.18 ± 10.55
Change (2–0)	0.490	0.139	0.758	0.096	0.128	0.799	0.240	0.155
Month 6	0.069	0.620	0.031a	0.885	0.744	0.056	0.096	0.200
			−20.98 ± 5.79 vs −18.92 ± 10.58
Change (6–0)	0.609	0.911	0.202	0.244	0.425	0.715	0.748	0.460
RNFLT
Baseline	0.910	0.013a	0.083	0.346	0.914	0.074	0.217	0.072
		170.63 ± 80.25 vs 189.38 ± 82.58
Month 2	0.385	0.137	0.329	0.295	0.162	0.666	0.295	0.689
Month 6	0.827	0.089	0.417	0.616	0.054	0.715	0.448	0.096

EECP enhanced external counterpulsation, BCVA best-corrected visual acuity in LogMAR, MD mean deviation, RNFLT retinal nerve fiber layer thickness

Independent t-test was conducted to compare visual function between EECP and control groups

^aDetailed parameter descriptions (EECP group vs control group) are displayed for cases involving a significant difference